Equities

Alligator Bioscience AB

Alligator Bioscience AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)1.33
  • Today's Change0.004 / 0.30%
  • Shares traded350.09k
  • 1 Year change+214.22%
  • Beta1.2496
Data delayed at least 15 minutes, as of Sep 23 2024 14:04 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy2
Outperform0
Hold0
Sell0
Strong Sell0

Share price forecast in SEK

The 3 analysts offering 12 month price targets for Alligator Bioscience AB have a median target of 2.00, with a high estimate of 2.40 and a low estimate of 2.00. The median estimate represents a 51.29% increase from the last price of 1.32.
High81.5%2.40
Med51.3%2.00
Low51.3%2.00

Earnings history & estimates in SEK

On Feb 26, 2021, losses of -0.44 per share.
The next earnings announcement is expected on Feb 06, 2025.
Average growth rate+10.68%
Alligator Bioscience AB reported annual 2023 losses of -0.55 per share on Feb 08, 2024.
Average growth rate+13.70%
More ▼

Revenue history & estimates in SEK

Alligator Bioscience AB (publ) had revenues for the full year 2023 of 58.11m. This was 62.78% above the prior year's results.
Average growth rate+108.96%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.